BACKGROUND Increasing studies investigating the association between steroid 5‐alpha
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …

Several polymorphisms in the 5α-reductase type 2 (SRD5A2) gene have been implicated as
risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) …

The pathogenetic mechanism of prostate cancer (PCa) has not been understood completely,
and gene polymorphisms have been demonstrated to play a critical role in the course. It has …

Abstract Steroid 5-α-reductase type 2 (SRD5a2) is a critical enzyme in androgen
metabolism. Two polymorphisms in the SRD5a2 gene, V89L (rs523349) and A49T …

PURPOSE: The SRD5A2 gene codes the steroid 5-reductase type II, a critical mediator of
androgen action, and the V89L and A49T polymorphisms of this gene may be associated …

The steroid 5-alpha reductase type II gene (SRD5A2) encodes the enzyme which converts
testosterone (T) to the more active androgen dihydrotestosterone. A non-synonymous single …

Abstract The steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2) gene plays a crucial
role in androgen metabolism pathway in human prostate. It encodes SRD5A2 enzyme …

It has been suggested that the activity of the steroid 5α-reductase type II enzyme (encoded
by the SRD5A2 gene) may be associated with prostate cancer risk and that population …

BACKGROUND Dihydrotestosterone (DHT) is believed to play an important role in prostate
carcinogenesis. Five alpha reductase type II (SRD5A2) and 3 beta‐hydroxysteroid …

Abstract Steroid 5-α-reductase type 2 (SRD5A2) V89L and A49T polymorphisms are thought
to play a crucial role in the androgen synthesis and metabolic pathway, but their …